ResearchEvaluation of the updated ABC-AF-bleeding score 2.0 in patients with atrial fibrillation treated with a direct oral anticoagulant or warfarin
ResearchMajor adverse cardiovascular and bleeding outcomes in paroxysmal vs. non-paroxysmal atrial fibrillation: an individual patient-level data analysis from COMBINE-AF
Jan 30, 2026Journal ArticleSystemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus Warfarin.Written by 1 Roon author & 12 others Via The American Heart Association Journals
ResearchAbelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial
ResearchBody Mass Index, Clinical Outcomes, and Mortality in Heart Failure: A Mendelian Randomization Study
ResearchDirect oral anticoagulants vs warfarin in Asian vs non-Asian patients with atrial fibrillation: a patient-level meta-analysis from COMBINE AF
ResearchEndothelial cell-related genetic variants identify LDL cholesterol-sensitive individuals who derive greater benefit from aggressive lipid lowering
ResearchMeta-analysis of genome-wide associations and polygenic risk prediction for atrial fibrillation in more than 180,000 cases
ResearchSequencing in over 50,000 cases identifies coding and structural variation underlying atrial fibrillation risk
ResearchGenome-wide association study meta-analysis provides insights into the etiology of heart failure and its subtypes
May 19, 2025Journal ArticleFactor XI Inhibition for Atrial Fibrillation: Where Do We Stand?Written by 1 Roon author & 2 others Via The American Heart Association Journals
ResearchLong-Acting Factor XI Inhibition and Periprocedural Bleeding: An Analysis From AZALEA-TIMI 71
Jun 23, 2025Journal ArticleAbelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial.Written by 1 Roon author & 16 others Via The American Heart Association Journals